EUS-guided fiducial placement after radical prostatectomy before targeted radiation therapy for prostate cancer recurrence

Yang, Julie; Abdel‐Wahab, May; Ribeiro, Afonso

doi:10.1016/j.gie.2011.01.045

Cited by 23 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EUS‐guided injection of fiducial markers to guide stereotactic radiotherapy is a novel, minimally invasive way to improve the accuracy of treatment. It is potentially more comfortable and accurate than the percutaneous route, and has been used for pancreatic, prostate and mediastinal cancers 49–51 …”

Section: Advances Beyond the Gutmentioning

confidence: 99%

See 1 more Smart Citation

Advances in gastrointestinal endoscopy

Kwan

2012

Internal Medicine Journal

View full text Add to dashboard Cite

Gastrointestinal endoscopy has undergone a remarkable expansion in its capabilities as a result of sophisticated technological advances in recent years. New imaging technologies, novel ablation and resection techniques, cutting‐edge endoscope development and creative extraluminal applications have taken gastrointestinal endoscopy to an exciting new level. An update on some of these advances is presented for the physician audience.

show abstract

Section: Advances Beyond the Gutmentioning

confidence: 99%

“…It is potentially more comfortable and accurate than the percutaneous route, and has been used for pancreatic, prostate and mediastinal cancers. [49][50][51]…”

Section: Injectionmentioning

confidence: 99%

Advances in gastrointestinal endoscopy

Kwan

2012

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…For target volume-de nition enhancement, radiotherapists often take advantage of image-registration techniques, mixing various image-exams, especially 18F-uoro-deoxy-2-d-glucose positron emission tomography (FDG-PET-CT), affording good help in RT-treatment planning and eventually in esophageal carcinoma management (Daisne and Gregoire, 2006;Moureau-Zabotto et al, 2005). Another technique to improve target-de nition refers to echoendoscopy (EUS)-assited ducial markers (FMs) implantation (Pishvaian et al, 2006;Yang et al, 2009;Yang et al, 2011). This technique was shown feasible without major adverse-events in many different primary cancers, (i.e., lung, pancreas, prostate cancers (Pishvaian et al, 2006;Yang et al, 2009;Yang et al, 2011), as well as esophagus carcinomas (Jelvehgaran et al, 2017;Jin et al, 2015;Machiels et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…Another technique to improve target-de nition refers to echoendoscopy (EUS)-assited ducial markers (FMs) implantation (Pishvaian et al, 2006;Yang et al, 2009;Yang et al, 2011). This technique was shown feasible without major adverse-events in many different primary cancers, (i.e., lung, pancreas, prostate cancers (Pishvaian et al, 2006;Yang et al, 2009;Yang et al, 2011), as well as esophagus carcinomas (Jelvehgaran et al, 2017;Jin et al, 2015;Machiels et al, 2015). The impact on the targeting of radiotherapy has been described for the prostatic cancer irradiation (Graf et al, 2010;Yang et al, 2009;Yang et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Impact of fiducial markers placements on the delineation of target volumes in radiation therapy for oesophageal cancer: final results of the FIDUCOR study

Moureau-Zabotto¹,

Caillol²,

Autret³

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose This prospective monocentric phase II study (FIDUCOR-study) aimed at the assessment of the impact of fiducial markers (FMs) implantation on conformal chemo-radiation therapy (CRT) planning in esophageal carcinoma (EC) patients. Methods/materials Fifteen EC patients were enrolled in the study. Each patient underwent two simulation CT-scans before (CT1) and after (CT2) FMs implantation, in the same position. FMs (3 mm length gold markers, preloaded in a 22G needle) were implanted after sedation, under EUS and X-Ray guidance, and were placed at the tumor’s extremities, and in the visible lymph nodes. Target delineation and treatment plan were both performed first on CT1 with the assistance of, diagnosis-CT, gastroscopy- and EUS-details, and second on CT2 using FMs and CT-data. The value of FMs implantation was assessed by the difference of growth-tumor-volume (GTV) and clinical-target-volume (CTV) between CT1-based and CT2-based delineation. A significant difference was defined as a ≥5 mm-difference on axial(x) or coronal(y) slices, a ≥10mm-difference on sagittal slices, or a ≥20%-difference in GTV. The impact on dose distribution in organs at risk (OAR) (lung, heart, liver) was also studied. Results Between 09/2014 and 12/2015, 15 patients could achieve fiducial procedures, without any complication. One FM migration occurred. We observed a significant modification of the GTV-dimension in 100% of the cases (15/15, 95%CI: [78.2;100.0]), mainly due to a difference in sagittal dimension with a mean variation of 11.2 mm and a difference> 10 mm for 8/15 patients (53.3%). One patient had a significant isocenter displacement as high as 20 mm. The esophagus tumor was not seen on the CT-scan in one patient due to its small size. One patient had a distant lymph node metastasis not visible on CT-scan. We observed no significant impact on OAR distribution. Conclusion In our study, FMs-implantation appeared to have positive impact on accurate volume definition in EC-patients. Registration trial number NCT02526134 since the 06-18-2013 ; URL https://clinicaltrials.gov/ct2/show/NCT02526134

show abstract

“…In addition, EUS FNA has been used to document prostate or bladder cancer recurrence manifesting as rectal linitis plastica [8–10]. EUS may also provide a therapeutic role by guiding drainage of pelvic fluid collections and with fiducial placement to guide radiation therapy for prostate cancer recurrence [11–16]. …”

Section: Introductionmentioning

confidence: 99%

Endoscopic-Ultrasound-Guided Tissue Sampling Facilitates the Detection of Local Recurrence and Extra Pelvic Metastasis in Pelvic Urologic Malignancy

Gleeson

Clain

Karnes

et al. 2012

Diagnostic and Therapeutic Endoscopy

View full text Add to dashboard Cite

Pelvic lymph node dissection is the gold standard for assessing nodal disease in prostate or bladder cancer and is superior to CT, MRI and PET staging. Endoscopic ultrasound (EUS) provides an alternative, less invasive method of cytohistologic material acquisition, but its performance in pelvic urologic malignancy is unknown. Therefore, our aim was to evaluate the diagnostic accuracy of EUS guided tissue sampling for these malignancies when compared to a composite cytohistologic and surgical gold standard. A median of 3 FNA passes were performed (n = 19 patients) revealing a sensitivity, specificity, PPV and NPV of 94.4% (72–99), 100% (2–100), 100% (80–100) and 50% (1–98) respectively. The perirectal space was the most frequently sampled location irrespective of the primary urological cancer origin. Final diagnosis established by EUS tissue sampling included bladder cancer (n = 1), bladder cancer local recurrence (n = 8), bladder cancer extra pelvic metastases (n = 1), prostate cancer (n = 2), prostate cancer local recurrence (n = 4), prostate cancer extra pelvic metastases (n = 1), testicular cancer extra pelvic metastases (n = 1) and a benign seminal vesicle (n = 1). EUS guided sampling of the gut wall, lymph nodes, or perirectal space yields suitable diagnostic material to establish the presence of primary, local recurrence or extra pelvic metastases of pelvic urologic malignancy.

show abstract

EUS-guided fiducial placement after radical prostatectomy before targeted radiation therapy for prostate cancer recurrence

Cited by 23 publications

References 10 publications

Advances in gastrointestinal endoscopy

Advances in gastrointestinal endoscopy

Impact of fiducial markers placements on the delineation of target volumes in radiation therapy for oesophageal cancer: final results of the FIDUCOR study

Endoscopic-Ultrasound-Guided Tissue Sampling Facilitates the Detection of Local Recurrence and Extra Pelvic Metastasis in Pelvic Urologic Malignancy

Contact Info

Product

Resources

About